

Aaron Waite, MD Contributes to Groundbreaking Research on Safe, Scar-Free Treatment for Corneal Epithelial Disease

August 22, 2024

Dr. Aaron Waite, renowned ophthalmologist and founder of Waite Vision, has made significant contributions to a recent scientific study that could revolutionize the treatment of corneal epithelial diseases. The study, titled ?Pilot Safety Study of a Microfabricated Device for Anterior Stromal Puncture to Treat Corneal Epithelial Disease in the Optical Axis,? explores the safety and efficacy of a novel device called the "plexitome." The device is designed to treat common and often debilitating eye conditions like recurrent corneal erosions (RCEs) and epithelial basement membrane dystrophy (EBMD) without the scarring typically associated with traditional treatments.

Dr. Waite has written an easy to read, laymen?s version of this article for anyone wanting to know more about the plexitome or its use in treatment. The article is titled ?Dr. Aaron Waite Contributed to Scientific Article on ?Plexitome? Safety.? It can be found on the Waite Vision website alongside many other resources for eye health and refractive procedures.

Corneal epithelial diseases, which can result from trauma, eye surgery, or degenerative conditions, have long posed challenges to patients and ophthalmologists alike. Treatments that involve anterior stromal

puncture?creating tiny punctures in the cornea to promote healing?are effective but often lead to visible scarring, especially when performed in the optical axis, the central part of the cornea critical for clear vision. The plexitome, an FDA-registered Class 1 medical device, offers a breakthrough solution. By using microfabricated technology, the plexitome creates small, shallow punctures in the cornea that aid in healing while avoiding the scarring which compromises vision.

Dr. Waite, alongside a team of distinguished colleagues, participated in this critical pilot study that tested the plexitome?s safety on 45 patients with various corneal epithelial conditions. The study spanned a diverse patient demographic, including men and women aged 21 to 83, all of whom were treated using the plexitome device. The study's results are promising: none of the patients exhibited visible corneal scarring, stromal haze, or infections following treatment, even 30 days after the procedure. These findings suggest the plexitome may be a safer alternative to traditional anterior stromal puncture methods, particularly for patients whose conditions require treatment in the optical axis.

The procedure itself is straightforward yet innovative. The plexitome device is gently pressed against the corneal surface to create micropunctures, each measuring about 5mm in diameter. This process may be repeated across the affected area of the cornea, depending on the severity and extent of the disease. Post-procedure care is customized to the doctor?s preference, with standard treatments including lubrication drops, antibiotic drops, and the use of bandage contact lenses. Within seven days of treatment, the majority of patients showed no signs of the micropuncture treatment when examined with a slit-lamp, a common tool used by ophthalmologists to closely inspect the cornea.

Dr. Waite and his research team are particularly encouraged by the lack of significant adverse events associated with the plexitome. Only two patients reported minor eye pain following the procedure, which was easily managed with over-the-counter pain relievers. These minimal side effects stand in stark contrast to the complications often associated with traditional corneal treatments, making the plexitome a compelling option for future use.

Dr. Waite?s involvement in this groundbreaking research underscores his commitment to advancing eye care and improving patient outcomes. As a respected leader in the field, Dr. Waite continues to push the boundaries of possibilities in ophthalmology, ensuring that patients at Waite Vision receive the most cutting-edge treatments available.

For more information about the study, Dr. Waite?s contributions, or to schedule an interview, please contact Waite Vision at (801) 876-6000 or visit Waite Vision?s website.

About Waite Vision

Waite Vision is a premier vision correction and eye care practice located in Lehi, Utah. Founded by Dr. Aaron Waite, the clinic is dedicated to providing state-of-the-art eye care services, including LASIK, cataract surgery, and treatment for corneal diseases. Dr. Waite and his team are committed to helping patients achieve their best possible vision through personalized, compassionate care.

Waite Vision

Waite Vision is superior vision correction center built around you. You have options, including LASIK, SMILE, PRK, ICLs, Refractive Lens Exchange and Corneal Cross-Linking. Let?s make blurry vision a thing of the past, so you can live life in focus.

Website: https://www.waitevision.com/

Email: info@waitevision.com

Phone: (801) 876-6000



Powered by PressAdvantage.com